Cystic fibrosis, aminoglycoside treatment and acute renal failure: The not so gentle micin

Pediatric Nephrology

Volumn 24, Issue 5, 2009, Pages 925-928

  Bockenhauer, Detlef ^a   Hug, Martin J ^b   Kleta, Robert ^c  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Acuterenal failure; Aminoglycoside; Children; Cystic fibrosis; Gentamicin

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; GENTAMICIN; RNA 12S; TOBRAMYCIN; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ACUTE KIDNEY FAILURE; CYSTIC FIBROSIS; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXCRETION; DRUG MONITORING; DRUG SAFETY; DRUG UPTAKE; GENE MUTATION; GENETIC SUSCEPTIBILITY; GLOMERULUS FILTRATION RATE; HUMAN; NEPHROTOXICITY; NONHUMAN; NOTE; OTOTOXICITY; PRESCRIPTION; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SINGLE DRUG DOSE;

ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; GENTAMICINS; HUMANS; INJECTIONS, INTRAVENOUS; KIDNEY; KIDNEY FAILURE, ACUTE; PSEUDOMONAS INFECTIONS; RISK FACTORS;

EID: 63649088944     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-008-1036-2     Document Type: Note

References (33)

1. Smyth A, Lewis S, Bertenshaw C, Choonara I, McGaw J, Watson A (2008) Case-control study of acute renal failure in patients with cystic fibrosis in the UK. Thorax 63:532-535
2. Bertenshaw C, Watson AR, Lewis S, Smyth A (2007) Survey of acute renal failure in patients with cystic fibrosis in the UK. Thorax 62:541-545
3. Pannu N, Nadim MK (2008) An overview of drug-induced acute kidney injury. Crit Care Med 36:S216-S223
4. Spahn CM, Prescott CD (1996) Throwing a spanner in the works: antibiotics and the translation apparatus. J Mol Med 74:423-439
5. Wirmer J, Westhof E (2006) Molecular contacts between antibiotics and the 30S ribosomal particle. Methods Enzymol 415:180-202
6. Moestrup SK, Cui S, Vorum H, Bregengård C, Bjørn SE, Norris K, Gliemann J, Christensen EI (1995) Evidence that epithelial glycoprotein 330/megalin mediates uptake of polybasic drugs. J Clin Invest 96:1404-1413
7. Vandewalle A, Farman N, Morin JP, Fillastre JP, Hatt PY, Bonvalet JP (1981) Gentamicin incorporation along the nephron: Autoradiographic study on isolated tubules. Kidney Int 19:529-539
8. Mingeot-Leclercq MP, Tulkens PM (1999) Aminoglycosides: Nephrotoxicity. Antimicrob Agents Chemother 43:1003-1012
9. Gainza FJ, Minguela JI, Lampreabe I (1997) Aminoglycoside-associated Fanconi's syndrome: An underrecognized entity. Nephron 77:205-211
10. Chou CL, Chen YH, Chau T, Lin SH (2005) Acquired bartter-like syndrome associated with gentamicin administration. Am J Med Sci 329:144-149
11. Finton CK, Bjorkland S, Zaloga GP, Uddin DE, Chernow B (1983) Gentamicin-induced hypomagnesemia. Am Surg 49:576-578
12. Bertino JS Jr, Booker LA, Franck PA, Jenkins PL, Franck KR, Nafziger AN (1993) Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. J Infect Dis 167:173-179
13. Smyth A, Tan KHV, Hyman-Taylor P, Mulheran M, Lewis S, Stableforth D, Knox A; TOPIC Study Group (2005) Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis - the TOPIC study: A randomised controlled trial. Lancet 365:573-578
14. Reiner NE, Bloxham DD, Thompson WL (1978) Nephrotoxicity of gentamicin and tobramycin given once daily or continuously in dogs. J Antimicrob Chemother 4 [Suppl A]:85-101
15. Rybak MJ, Abate BJ, Kang SL, Ruffing MJ, Lerner SA, Drusano GL (1999) Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 43:1549-1555
16. Twiss J, Byrnes C, Johnson R, Holland D (2005) Nebulised gentamicin - suitable for childhood bronchiectasis. Int J Pharm 295:113-119
17. Geller DE, Pitlick WH, Nardella PA, Tracewell WG, Ramsey BW (2002) Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 122:219-226
18. Hoffmann IM, Rubin BK, Iskandar SS, Schechter MS, Nagaraj SK, Bitzan MM (2002) Acute renal failure in cystic fibrosis: Association with inhaled tobramycin therapy. Pediatr Pulmonol 34:375-377
19. Smith CR, Lipsky JJ, Laskin OL, Hellmann DB, Mellits ED, Longstreth J, Lietman PS (1980) Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. N Engl J Med 302:1106-1109
20. Pitt TL, Sparrow M, Warner M, Stefanidou M (2003) Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents. Thorax 58:794-796
21. Kresken M, Hafner D, Schmitz FJ, Wichelhaus T (2006) Resistenzsituation bei klinisch wichtigen Infektionserregern gegenüber Antibiotika in Deutschland und im mitteleuropäischen Raum. Bericht über die Ergebnisse einer multizentrischen Studie der Arbeitsgemeinschaft Empfindlichkeitsprüfungen & Resistenz der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. aus dem Jahre 2004. Antiinfectives Intelligence
22. Kleta R, Brune T, Harms E (1999) Cystic fibrosis and metabolic alkalosis in children - revisited. Miner Electrolyte Metab 25:210
23. Ballestero Y, Hernandez MI, Rojo P, Manzanares J, Nebreda V, Carbajosa H, Infante E, Baro M (2006) Hyponatremic dehydration as a presentation of cystic fibrosis. Pediatr Emerg Care 22:725-727
24. Hoppe B, von Unruh GE, Blank G, Rietschel E, Sidhu H, Laube N, Hesse A (2005) Absorptive hyperoxaluria leads to an increased risk for urolithiasis or nephrocalcinosis in cystic fibrosis. Am J Kidney Dis 46:440-445
25. Andersen HU, Lanng S, Pressler T, Laugesen CS, Mathiesen ER (2006) Cystic fibrosis-related diabetes: The presence of microvascular diabetes complications. Diabetes Care 29:2660-2663
26. Abramowsky CR, Swinehart GL (1982) The nephropathy of cystic fibrosis: A human model of chronic nephrotoxicity. Hum Pathol 13:934-939
27. Rossi R, Kleta R, Ehrich JH (1999) Renal involvement in children with malignancies. Pediatr Nephrol 13:153-162
28. Prezant TR, Agapian JV, Bohlman MC, Bu X, Oztas S, Qiu WQ, Arnos KS, Cortopassi GA, Jaber L, Rotter JI, Shohat M, Fischel-Ghodsian N (1993) Mitochondrial ribosomal RNA mutation associated with both antibiotic-induced and non-syndromic deafness. Nat Genet 4:289-294
29. Dodge JA, Lewis PA, Stanton M, Wilsher J (2007) Cystic fibrosis mortality and survival in the UK: 1947-2003. Eur Respir J 29:522-526
30. Bellis G, Cazes MH, Parant A, Gaimard M, Travers C, Le Roux E, Ravilly S, Rault G (2007) Cystic fibrosis mortality trends in France. J Cyst Fibros 6:179-186
31. Slieker MG, Uiterwaal CS, Sinaasappel M, Heijerman HG, van der Laag J, van der Ent CK (2005) Birth prevalence and survival in cystic fibrosis: a national cohort study in the Netherlands. Chest 128:2309-2315
32. Schuler D, Sermet-Gaudelus I, Wilschanski M, Ballmann M, Dechaux M, Edelman A, Hug M, Leal T, Lebacq J, Lebecque P, Lenoir G, Stanke F, Wallemacq P, Tümmler B, Knowles MR (2004) Basic protocol for transepithelial nasal potential difference measurements. J Cyst Fibros 3 [Suppl 2]:151-155
33. Hug MJ, Tummler B (2004) Intestinal current measurements to diagnose cystic fibrosis. J Cyst Fibros 3 [Suppl 2]:157-158